New Synchrony Study Finds Homeowners Underestimate Lifetime Home Maintenance and Repair Costs by More Than $250,000

Synchrony (NYSE: SYF), a leading consumer financing company, today released findings from its new national study, Lifetime of ...

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...